


# Interim Results From a Phase 1/2, Open-Label, Dose-Escalation Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenström's Macroglobulinemia

Sheeba K. Thomas<sup>1</sup>, Wael Harb<sup>2</sup>, Thaddeous Beck<sup>3</sup>, Nashat Gabrail<sup>4</sup>, M. Lia Palomba<sup>5</sup>, Stephen Ansell<sup>6</sup>, Herbert Eradat<sup>7</sup>, Edward Libby<sup>8</sup>, Ranjana Advani<sup>9</sup>, Julio Hajdenberg<sup>10</sup>, Leonard Heffner<sup>11</sup>, James Hoffman<sup>12</sup>, David Vesole<sup>13</sup>, Lindsey Simov<sup>14</sup>, Nancy Wyant<sup>14</sup>, Julie Brevard<sup>14</sup>, Sudhir Agrawal<sup>14</sup>, James O'Leary<sup>14</sup>

<sup>1</sup>University of Texas M.D. Anderson Cancer Center, Houston, TX; <sup>2</sup> Horizon Oncology Center, Lafayette, IN; <sup>3</sup> Highlands Oncology Group, Fayetteville, AR; <sup>4</sup> Gabrail Cancer Center, Canton, OH; <sup>5</sup> Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; <sup>6</sup> Division of Hematology, Mayo Clinic, Rochester, MN; <sup>7</sup> David Geffen School of Medicine, University of California Los Angeles, CA; <sup>8</sup> Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA; <sup>9</sup> Medical Oncology, Stanford University Medical Center, Stanford, CA; <sup>10</sup> University of Florida Health Cancer Center at Orlando Health, Orlando, FL; <sup>11</sup> Winship Cancer Institute, Emory University, Atlanta, GA; <sup>12</sup> Division of Hematology-Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL; <sup>13</sup> John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ; <sup>14</sup> Idera Pharmaceuticals, Inc., Cambridge, MA

## Rationale for Toll-like Receptor Antagonism as a Potential Therapeutic Approach in Waldenström's Macroglobulinemia


- Waldenström's macroglobulinemia (WM) is a rare, indolent B-cell lymphoma characterized by lymphoplasmacytic cell infiltration of bone marrow and elevated serum levels of immunoglobulin M (IgM) protein
- About 90% of WM patients harbor the MYD88 L265P oncogenic mutation; MYD88 is an adapter protein in the Toll-like receptor (TLR) pathway
- In preclinical studies, the MYD88 L265P mutation was shown to amplify TLR7 and 9 signaling, and knockdown of these TLRs potently suppressed NF-κB activity and promoted apoptosis in B-cell lymphoma cell lines harboring the mutation<sup>1</sup>
- TLR7, 8 and 9 are expressed on the endosome of human B-cells and dendritic cells and recognize nucleic acid ligands
- IMO-8400 is a novel investigational oligonucleotide-based antagonist of TLR7, 8 and 9



- In preclinical studies in human cell lines of WM harboring the MYD88 L265P mutation, IMO-8400 inhibited key cell signaling pathways, including NF-κB, BTK, STAT-3 and IRAK-4<sup>2</sup>
- In preclinical tumor models harboring the MYD88 L265P mutation, IMO-8400 inhibited tumor growth and immunoglobulin M (IgM) protein production. In addition, tumor growth inhibition was correlated with suppression of systemic cytokines such as IL-10, IL-2R, IP-10 and MIG<sup>2</sup>
- In Phase 1 and 2 clinical trials in healthy subjects (N=30) and in patients with autoimmune disease (N=35), IMO-8400 was generally well tolerated and demonstrated evidence of clinical activity<sup>3,4</sup>
- Based on these data, we initiated a Phase 1/2 clinical trial of IMO-8400 in WM, the first study of a drug candidate specifically targeting the MYD88 L265P mutation

<sup>1</sup> Lim, et al. AACR, 2013; <sup>2</sup> Bhagat, et al. AACR, 2014; <sup>3</sup> Bhagat, et al. FOCUS, 2013; <sup>4</sup> Balak, et al. AAD, 2015. Graphic adapted from: Cancer Res. 2013; 73 Suppl. 1:2332.

## Design of an Open-Label Phase 1/2 Dose-Escalation Clinical Trial in Patients with WM



- IMO-8400 administered by subcutaneous injection
- Serum IgM and M-protein assessed at screening, Weeks 9, 17, 23, end of treatment, and end of study
- Bone marrow biopsies conducted at screening and end of treatment
- Serum collected at screening, Week 1 of every 8 week cycle, and end of treatment for cytokine assessment
- PCR-based genetic screening used to determine MYD88 L265P mutation status following enrollment

## Study Objectives

- Primary**
  - Safety and tolerability
- Secondary**
  - Preliminary evidence of efficacy based on international guidelines for classifying a clinical response<sup>1</sup>
  - Identification of an optimal dose for further clinical evaluation
  - Characterization of the pharmacokinetics of escalating dose levels
- Exploratory**
  - Associations between the treatment effect of IMO-8400 and selected immunologic markers of disease activity (e.g., serum cytokines)

<sup>1</sup> Owen, et al. British Journal of Haematology, 2012.

## Eligibility Criteria

### Major Inclusion Criteria

- Primary diagnosis established according to criteria of the Second International Workshop on WM<sup>1</sup>
- Received at least one course of therapy consistent with the recommendations for "first-line therapy" from the Fourth International Workshop on WM<sup>2</sup>
- Relapsed or refractory based on the criteria for assessing response from the Sixth International Workshop on WM<sup>3</sup>
- Serum monoclonal immunoglobulin M-protein  $\geq 0.5$  g/dL at screening

### Major Exclusion Criteria

- Received cytotoxic chemotherapy within the past 3 weeks or rituximab within the past 2 months
- At initiation of study drug, receiving concomitant chronic systemic corticosteroid therapy  $>20$  mg of prednisone daily
- Active autoimmune cytopenia (anemia, thrombocytopenia, leukopenia) requiring concomitant therapy

<sup>1</sup> Owen, et al. Seminars in Oncology, 2003; <sup>2</sup> Dimopoulos, et al. Journal of Clinical Oncology, 2009; <sup>3</sup> Treon, et al. Clinical Lymphoma, Myeloma and Leukemia, 2011.

## Patient Disposition and Analysis Populations

- 19 patients were enrolled as of August 2015 data cut-off
- Efficacy evaluable population (N=15) excluded 2 patients who initiated treatment within 1 week of data cut-off and 2 patients who did not complete at least 1 cycle of therapy
- Median follow-up of 24 weeks (range 3-50 weeks)
- 13 activated clinical sites in the United States

Population	0.6 mg/kg/wk	1.2 mg/kg/wk	2.4 mg/kg/wk	Overall
Enrolled / safety population	6	5	8	19
Patient status				
• Ongoing	0	0	3 (38%)	3 (16%)
• Completed 24 weeks of therapy	5 (83%)	2 (40%)	3 (38%)	10 (53%)
• Discontinued study				
- Due to dose-limiting toxicity	0	0	1 (12%)	1 (5%)
- Due to adverse event	0	0	0	0
- Disease progression	0	2 (40%)	0	2 (11%)
- Other	1 (17%)	1 (20%)	1 (12%)	3 (16%)
Efficacy evaluable population*	5 (83%)	4 (80%)	6 (75%)	15 (79%)
• Completed $\geq 1$ cycle of IMO-8400	5 (83%)	4 (80%)	5 (62%)	14 (74%)

\* Includes patients who completed  $\geq 1$  cycle of therapy or those who discontinued due to progressive disease or dose-limiting toxicity

## Baseline Patient Characteristics

Characteristic	Total (N=19)
Median age (range) – year	68 (48-94)
Sex – n (%)	
Male	13 (68%)
Female	6 (32%)
iPSSWM – n (%)	
Low	7 (37%)
Medium	10 (53%)
High	2 (11%)
Disease status – n (%)	
Relapsed	15 (79%)
Refractory*	4 (21%)
Median paraprotein levels	
Serum IgM (range) – mg/dL	2225 (785-5750)
M-protein (range) – g/dL	0.96 (0.06-2.71)
Median hemoglobin (range) – g/dL	11.3 (7.6-13.9)
Median serum $\beta$ 2-microglobulin (range) – mg/L	3.42 (1.28-13.10)
Median platelet count (range) – thousand/mm <sup>3</sup>	240 (50-479)
MYD88 L265P mutation status – n (%)	
Positive	15 (79%)
Negative	3 (16%)
Indeterminate/ Missing	1 (5%)

\* Refractory defined as last treatment regimen received within prior 6 months

## History of Prior Treatment

Characteristic	Total (N=19)
Median no. of previous treatment regimens (range)	2 (1-7)
Most Common Therapies** – n (%)	
Rituximab	17 (89.5%)
Bortezomib	8 (42.1%)
Cyclophosphamide	8 (42.1%)
Cladribine	7 (36.8%)
Dexamethasone	5 (26.3%)
Prednisone	4 (21.1%)
Fludarabine	3 (15.8%)
Experimental	2 (10.5%)
Vincristine	2 (10.5%)
Ibrutinib	1 (5.3%)

\*\* Excludes treatments/regimens reported only once, with the exception of ibrutinib


## Summary of Treatment-Emergent Adverse Events

- IMO-8400 was generally well tolerated at all dose levels
- Most reported adverse events (AEs) deemed related or possibly related to study drug were mild or moderate (CTCAE grade 1 or 2)
- The most common AEs observed were fatigue, injection site erythema, headache, injection site pain, nausea and pain in extremity
- Reported injection site reactions included grade 1 erythema, grade 1 pain and grade 1 induration
  - No injection site blistering, necrosis, pruritus, ulceration or tenderness were reported
- Grade 3 AEs reported as possibly or probably related to study drug included neutropenia, anemia and arthritis
  - 1 of 8 patients treated with 2.4 mg/kg in the safety population had a dose-limiting toxicity (DLT) deemed possibly related to study drug. This patient experienced a grade 3 probable flare of pre-existing arthritis
- No deaths or grade 4 events were reported

## Incidence of Frequently Reported Treatment-Emergent Adverse Events (AEs Experienced by Two or More Patients)


Preferred Term	Subjects Experiencing All Grades
Fatigue	3 (16%)
Injection site erythema	3 (16%)
Headache	3 (16%)
Injection site pain	3 (16%)
Nausea	3 (16%)
Pain in extremity	3 (16%)
Arthralgia	2 (10%)
Anemia	2 (10%)
Dehydration	2 (10%)
Diarrhea	2 (10%)
Hematoma	2 (10%)
Neutropenia	2 (10%)
Night sweats	2 (10%)
Upper respiratory tract infection	2 (10%)

## Maximal Decrease in Serum IgM or M-protein (Best Observed of Either) in Efficacy Evaluable Patients



\* 1 evaluable patient discontinued due to a DLT before a follow-up IgM level was obtained

## Serum IgM and M-protein Were Highly Correlated Regardless of Response Status



• Correlation analysis of serum IgM and M-protein included values at multiple time points for the efficacy evaluable population (N=15)


## Summary of Responses, Based on International Guidelines for Classifying a Clinical Response\*

Dose Level (mg/kg)	Number of Prior Therapies	Regimen Prior to Study 401	Best Clinical Response	Time to Best Response	Bone Marrow Response
0.6	1	rituximab, ~2 months prior	MR	~24 wks	Not assessed
0.6	2	rituximab, ~11 months prior	PR	~24 wks	Not assessed
1.2	2	bortezomib/ dexamethasone, ~2 months prior	MR	~28 wks	Yes
2.4	6	ibrutinib, ~2 months prior	PR	~8 wks	Yes
2.4	1	rituximab/ bortezomib/ cyclophosphamide, ~5 years prior	MR	~16 wks	No (stable)
2.4	2	cladribine, ~3 years prior	MR	~8 wks	Yes

\* Clinical response criteria include serum IgM or M-protein, extramedullary disease assessment, bone marrow assessment and disease symptoms

- Among 6 evaluable patients treated at the highest dose level studied to date (2.4 mg/kg), 3 had responses and 2 had stable disease
- Trend in time to first response:
  - ~25 weeks for the 0.6 and 1.2 mg/kg cohorts combined
  - ~11 weeks for the 2.4 mg/kg cohort


## Dose-Dependent Changes in Hemoglobin and Hematocrit



- Improvements in hemoglobin and hematocrit were observed in the 2.4 mg/kg cohort, when compared to the 0.6 and 1.2 mg/kg cohorts

\* No observations for 1.2 mg/kg cohort at C3W17 due to 2 unevaluable samples

## Change in Serum IL-10 from Baseline to Last Observation



- Responders had a 16.5% median decrease in serum IL-10; at baseline, these patients had a median serum IL-10 level above the lower limit of detection
- Non-responders had a median serum IL-10 level below the lower limit of detection at baseline, and no change was observed through the last observation
- There was a significant correlation between change in M-protein and change in IL-10 (rho=0.71, p=0.01)

## Summary of IMO-8400 Pharmacokinetics

Dose mg/kg	Frequency	Number of Patients [Week 1 / Week 13]	AUC <sub>0-24</sub> , ng·h/mL (SD) [Week 13]	Accumulation Ratio [Week 13 / Week 1]
0.6	1x weekly	6 / 5	2990 (±1244)	1.17
1.2	1x weekly	4 / 2	7308 (±378)	0.90
1.2	2x weekly	8 / 3	7992 (±1244)	1.00


Methods: Sample Time Points: pre-dose, 1, 2 and 4 hours post-dose on Week 1, Week 5 and Week 13. Plasma (K2-EDTA) samples were analyzed using a validated hybridization ELISA method. For human plasma the assay LOQ is 10.0 ng/mL. Pharmacokinetic analysis of plasma assay results was performed using Phoenix WinNonlin (version 6.4, Certara, Princeton, NJ). Non-compartmental methods (linear trapezoidal interpolation) were used to calculate pharmacokinetic parameters, where possible.

### Summary of Pharmacokinetic (PK) Data

- PK results showed evidence of dose-dependent exposure
- Twice weekly compared to once weekly administration of 1.2 mg/kg did not impact PK
- There was no evidence of drug accumulation at Week 13

## Case Report: Partial Response in a Patient with Refractory Disease

- 67-year-old white female first diagnosed with WM in Nov. 2009
- Previously treated with 6 regimens:
  - 1/2010 - 2/2010: rituximab for 4 weekly infusions with PD
  - 7/2010 - 10/2010: rituximab, bortezomib and dexamethasone x 5 cycles with PR
  - 1/2011 - 9/2012: rituximab maintenance x 6 cycles
  - 6/2013 - 1/2014: pomalidomide x 6 cycles with PR
  - 2/2014 - 4/2014: rituximab x 2 cycles
  - 7/2014 - 10/2014: ibrutinib x 3 cycles with PD
- Symptoms prior to initiating IMO-8400 treatment included diarrhea and fatigue
- Started treatment with IMO-8400 at a dose of 2.4 mg/kg per week
- Achieved PR by Week 9 on study
- PR was associated with an improvement in: baseline symptoms, intestinal wall thickening, hemoglobin (3.2 g/dL increase),  $\beta$ 2-microglobulin (46% decrease)
- Bone marrow disease burden decreased from 15% (baseline) to 10% (end of treatment)
- Completed full course of treatment on study, but did not roll over to extension study due to one episode of grade 3 neutropenia



• CT imaging of the pelvis showed diffuse bowel wall thickening at baseline, with improvement demonstrated at end of treatment

## CONCLUSIONS

### Safety

- IMO-8400 was generally well tolerated at dose levels of 0.6, 1.2 and 2.4 mg/kg (1.2 mg/kg twice) per week
- The Maximum Tolerated Dose of IMO-8400 has not yet been identified

### Clinical activity

- In the highest dose cohort studied to date (2.4 mg/kg):
  - There were 3 responses and 2 stable disease out of 6 patients with evaluable disease treated to date
  - Median time to first response ~10.5 weeks
  - Improvements in symptoms, hemoglobin and bone marrow were seen
  - One of these responders was refractory to ibrutinib

### Summary

- These data in patients with WM provide the first clinical evidence supporting inhibition of the TLR pathway as a potential therapeutic approach for B-cell lymphomas harboring the MYD88 L265P oncogenic mutation
- Exploration of higher IMO-8400 dose levels in this patient population is warranted